NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
MOUNJARO (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2022.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOUNJARO (tirzepatide) is a dual G-protein coupled receptor agonist targeting GIP and GLP-1 receptors, approved in May 2022 for type 2 diabetes management. It works by stimulating insulin secretion in a glucose-dependent manner and reducing appetite, addressing both glycemic control and weight reduction. Administered as a subcutaneous injection, it represents a novel mechanism within the incretin-based therapy class.
$2.4BPart D
PeakGrowing
15.5 years to LOEMOUNJARO is in peak commercial phase with strong growth trajectory, driving expansion of cross-functional teams across commercial, medical affairs, and market access functions at Eli Lilly.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Started Aug 2026
224 enrolled
Obesity and Overweight
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
Started May 2026
30 enrolled
Psoriatic ArthritisOsteoarthitisKnee+12 more
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Started Feb 2026
344 enrolled
Diabetes Mellitus, Type 2ObesityOverweight
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Started Feb 2026
60 enrolled
Idiopathic Intracranial Hypertension (IIH)
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
Worked on MOUNJARO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.